107 related articles for article (PubMed ID: 36008273)
1. Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan.
Kanazu M; Shimokawa M; Saito R; Mori M; Tamura A; Okano Y; Fujita Y; Endo T; Motegi M; Takata S; Kita T; Sukoh N; Takenoyama M; Atagi S
J Geriatr Oncol; 2022 Nov; 13(8):1216-1222. PubMed ID: 36008273
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan.
Shimokawa M; Kanazu M; Saito R; Mori M; Tamura A; Okano Y; Fujita Y; Endo T; Motegi M; Takata S; Kita T; Sukoh N; Mizuki F; Takenoyama M; Atagi S
Thorac Cancer; 2023 Jun; 14(17):1597-1605. PubMed ID: 37073452
[TBL] [Abstract][Full Text] [Related]
3. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.
Hurria A; Togawa K; Mohile SG; Owusu C; Klepin HD; Gross CP; Lichtman SM; Gajra A; Bhatia S; Katheria V; Klapper S; Hansen K; Ramani R; Lachs M; Wong FL; Tew WP
J Clin Oncol; 2011 Sep; 29(25):3457-65. PubMed ID: 21810685
[TBL] [Abstract][Full Text] [Related]
4. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
[TBL] [Abstract][Full Text] [Related]
5. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
Singh AK; Lockett MA; Bradley JD
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
[TBL] [Abstract][Full Text] [Related]
7. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials.
Mandrekar SJ; Northfelt DW; Schild SE; Foster NR; Bot B; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Adjei AA; Jett JR
J Thorac Oncol; 2006 Jul; 1(6):556-63. PubMed ID: 17409917
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Observational Study of Pulmonary Resection for Non-small Cell Lung Cancer in Patients Older Than 75 Years.
Yano T; Kawashima O; Takeo S; Adachi H; Tagawa T; Fukuyama S; Shimokawa M;
Semin Thorac Cardiovasc Surg; 2017; 29(4):540-547. PubMed ID: 29698655
[TBL] [Abstract][Full Text] [Related]
9. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
14. Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.
Chao HH; Berman AT; Simone CB; Ciunci C; Gabriel P; Lin H; Both S; Langer C; Lelionis K; Rengan R; Hahn SM; Prabhu K; Fagundes M; Hartsell W; Mick R; Plastaras JP
J Thorac Oncol; 2017 Feb; 12(2):281-292. PubMed ID: 27826034
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
16. Elderly patients with advanced NSCLC: The value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity.
Almodovar T; Teixeira E; Barroso A; Soares M; Queiroga HJ; Cavaco-Silva J; Barata F
Pulmonology; 2019; 25(1):40-50. PubMed ID: 30266308
[TBL] [Abstract][Full Text] [Related]
17. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
[TBL] [Abstract][Full Text] [Related]
18. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer.
Wildes TM; Ruwe AP; Fournier C; Gao F; Carson KR; Piccirillo JF; Tan B; Colditz GA
J Geriatr Oncol; 2013 Jul; 4(3):227-34. PubMed ID: 23795224
[TBL] [Abstract][Full Text] [Related]
19. Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
Lavole A; Mazieres J; Schneider S; Brosseau S; Kiakouama L; Greillier L; Guihot A; Abbar B; Baron M; Makinson A; Langlais A; Morin F; Spano JP; Cadranel J;
Lung Cancer; 2021 Aug; 158():146-150. PubMed ID: 34217967
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
Tanaka H; Taima K; Tanaka Y; Itoga M; Ishioka Y; Nakagawa H; Baba K; Hasegawa Y; Takanashi S; Tasaka S
Med Oncol; 2018 Feb; 35(3):34. PubMed ID: 29423683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
